Gefjon Pharma
Developer of a vaccine platform based on hyper-vesiculating outer membrane vesicles (OMVs) and a genetically modified, high-yield bacterial expression strain. Focuses on a broad‑spectrum E. coli vaccine for poultry with validated proof of concept for both the vaccine and an aerosol delivery method. Engages in collaborative R&D with academic partners and pursues commercialization and grant-funded development.
Industries
Nr. of Employees
small (1-50)
Gefjon Pharma
Products
Broad‑spectrum E. coli vaccine for poultry
A vaccine candidate developed from an OMV-based platform intended to protect poultry against multiple E. coli strains; proof of concept demonstrated for vaccine and aerosol delivery.
Broad‑spectrum E. coli vaccine for poultry
A vaccine candidate developed from an OMV-based platform intended to protect poultry against multiple E. coli strains; proof of concept demonstrated for vaccine and aerosol delivery.
Services
Joint R&D projects and research collaborations with academic and industry partners to develop platform applications.
Securing commercialization rights and preparing platform-derived products for market entry through licensing and partner agreements.
Joint R&D projects and research collaborations with academic and industry partners to develop platform applications.
Securing commercialization rights and preparing platform-derived products for market entry through licensing and partner agreements.
Expertise Areas
- Vaccine development (bacterial, veterinary)
- Platform biomanufacturing and process optimization
- Outer membrane vesicle (OMV) technologies
- Aerosol/respiratory vaccine delivery
Key Technologies
- Outer membrane vesicles (OMVs)
- Bacterial strain genetic engineering
- High-yield protein expression systems
- Extraction and downstream processing for biologics
News & Updates
Company announced receipt of SME status from EMA.
Partner DI Biosolutions featured the company's activities.
Public post about a visit to a manufacturing partner's production sites.
Company pitched at a Demo Day event hosted by BioInnovation Institute.
Announcement introducing a new advisory board member.
Public post announcing completion of the company's first supplier audit.
Company announced receipt of SME status from EMA.
Partner DI Biosolutions featured the company's activities.
Public post about a visit to a manufacturing partner's production sites.
Company pitched at a Demo Day event hosted by BioInnovation Institute.
Announcement introducing a new advisory board member.
Public post announcing completion of the company's first supplier audit.